Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Goldenberg

Showing results (671-680 of 968) with videos related to

Pageof 97
Sort By:
EJNMMI Research|September 6, 2019
A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancerFortuné M K Elekonawo, Susanne Lütje, Gerben M Franssen, et al.
Molecular Immunology|December 1, 1995
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2S O Leung, D M Goldenberg, A S Dion, et al.
Bioconjugate Chemistry|June 15, 2010
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complexWilliam J McBride, Christopher A D'Souza, Robert M Sharkey, et al.
International Journal of Cancer|May 2, 1997
The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibodyM J Mattes, L B Shih, S V Govindan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study GroupF L Moffat, C M Pinsky, L Hammershaimb, et al.
Blood|January 27, 2010
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysRhona Stein, Pankaj Gupta, Xiaochuan Chen, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
AIDS and Behavior|October 21, 2011
Exploring the impact of underage sex work among female sex workers in two Mexico-US border citiesShira M Goldenberg, Gudelia Rangel, Alicia Vera, et al.
Molecular Pharmaceutics|November 18, 2014
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drugSerengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, et al.
Blood|August 7, 2004
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignanciesRhona Stein, Zhengxing Qu, Thomas M Cardillo, et al.
Pageof 97

Showing results (671-680 of 968) with videos related to

Sort By:
Pageof 97
EJNMMI Research|September 6, 2019
A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancerFortuné M K Elekonawo, Susanne Lütje, Gerben M Franssen, et al.
Molecular Immunology|December 1, 1995
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2S O Leung, D M Goldenberg, A S Dion, et al.
Bioconjugate Chemistry|June 15, 2010
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complexWilliam J McBride, Christopher A D'Souza, Robert M Sharkey, et al.
International Journal of Cancer|May 2, 1997
The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibodyM J Mattes, L B Shih, S V Govindan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study GroupF L Moffat, C M Pinsky, L Hammershaimb, et al.
Blood|January 27, 2010
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysRhona Stein, Pankaj Gupta, Xiaochuan Chen, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
AIDS and Behavior|October 21, 2011
Exploring the impact of underage sex work among female sex workers in two Mexico-US border citiesShira M Goldenberg, Gudelia Rangel, Alicia Vera, et al.
Molecular Pharmaceutics|November 18, 2014
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drugSerengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, et al.
Blood|August 7, 2004
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignanciesRhona Stein, Zhengxing Qu, Thomas M Cardillo, et al.
Pageof 97